Register for our free email digests:
Zambon Co. SPA
Latest From Zambon Co. SPA
Newron CEO Stefan Weber joins Scrip to discuss the company's recently approved Parkinson's therapy Xadago (safinamide), as well as development timelines for Newron's other pipeline candidates.
First new chemical entity for Parkinson's to clear FDA in 10 years, Xadago has a narrower indication than Teva's Azilect and similar pricing.
After overcoming regulatory hurdles, Newron may have tough time competing in US against market stalwart Azilect; eight Parkinson's drugs are in Phase III trials.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2017
- Therapeutic Areas
- Zambon Group SPA
- Western Europe
- Company Type
- Midsize European
- Parent & Subsidiaries
- Zambon Co. SPA
- Senior Management
- Roberto Consonni, CEO
- Contact Info
Zambon Co. SPA
Phone: (39) 02 665241
Via Lillo del Duca 10
Bresso (Milan), 20091
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.